Opexa Therapeutics   Report issue

For profit Phase 2
Founded: Houston TX United States (1986)
Status: Acquired by Acer Therapeutics (2017) → now Zevra Therapeutics (2023)

Organization Overview

First Clinical Trial
2002
NCT00587691
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Opexa Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

imilecleucel-t (1 trial)

tovaxin (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Autoimmune Diseases (Phase 2)

Autoimmune Diseases of the Nervous System (Phase 2)

Disease Progression (Phase 2)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Chronic Progressive (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Neoplasm Metastasis (Phase 2)

Nervous System Diseases (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2